- Home
- IMNN vs APLM Comparison
IMNN vs APLM Comparison
Compare IMNN & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- APLM
- Stock Information
- Founded
- IMNN 1982
- APLM 2016
- Country
- IMNN United States
- APLM United States
- Employees
- IMNN N/A
- APLM N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- APLM Blank Checks
- Sector
- IMNN Health Care
- APLM Finance
- Exchange
- IMNN Nasdaq
- APLM Nasdaq
- Market Cap
- IMNN 15.1M
- APLM 15.6M
- IPO Year
- IMNN 1985
- APLM N/A
- Fundamental
- Price
- IMNN $1.02
- APLM $0.14
- Analyst Decision
- IMNN Strong Buy
- APLM Strong Buy
- Analyst Count
- IMNN 2
- APLM 2
- Target Price
- IMNN $21.50
- APLM $4.25
- AVG Volume (30 Days)
- IMNN 227.1K
- APLM 876.0K
- Earning Date
- IMNN 11-12-2024
- APLM 08-14-2024
- Dividend Yield
- IMNN N/A
- APLM N/A
- EPS Growth
- IMNN N/A
- APLM N/A
- EPS
- IMNN N/A
- APLM N/A
- Revenue
- IMNN N/A
- APLM $2,101,000.00
- Revenue This Year
- IMNN N/A
- APLM N/A
- Revenue Next Year
- IMNN N/A
- APLM N/A
- P/E Ratio
- IMNN N/A
- APLM N/A
- Revenue Growth
- IMNN N/A
- APLM 70.54
- 52 Week Low
- IMNN $0.48
- APLM $0.11
- 52 Week High
- IMNN $3.65
- APLM $2.06
- Technical
- Relative Strength Index (RSI)
- IMNN 45.77
- APLM 48.96
- Support Level
- IMNN $0.99
- APLM $0.13
- Resistance Level
- IMNN $1.08
- APLM $0.17
- Average True Range (ATR)
- IMNN 0.05
- APLM 0.01
- MACD
- IMNN 0.00
- APLM -0.00
- Stochastic Oscillator
- IMNN 33.33
- APLM 34.48
About IMNN Imunon Inc.
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.